Free Trial

Nanobiotix (NBTX) Competitors

Nanobiotix logo
$5.26 +0.04 (+0.77%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NBTX vs. NRIX, SANA, LENZ, ZYME, ORIC, NAGE, MENS, SION, REPL, and GHRS

Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include Nurix Therapeutics (NRIX), Sana Biotechnology (SANA), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Oric Pharmaceuticals (ORIC), Niagen Bioscience (NAGE), Jyong Biotech (MENS), Sionna Therapeutics (SION), Replimune Group (REPL), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.

Nanobiotix vs. Its Competitors

Nurix Therapeutics (NASDAQ:NRIX) and Nanobiotix (NASDAQ:NBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Nanobiotix has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. Nanobiotix's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics-234.57% -45.26% -34.71%
Nanobiotix N/A N/A N/A

Nurix Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, Nanobiotix has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

38.8% of Nanobiotix shares are owned by institutional investors. 7.4% of Nurix Therapeutics shares are owned by insiders. Comparatively, 3.5% of Nanobiotix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Nanobiotix has lower revenue, but higher earnings than Nurix Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$54.55M15.71-$193.57M-$2.61-4.30
Nanobiotix$39.18M6.33-$73.73MN/AN/A

In the previous week, Nurix Therapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 16 mentions for Nurix Therapeutics and 0 mentions for Nanobiotix. Nanobiotix's average media sentiment score of 1.87 beat Nurix Therapeutics' score of 0.30 indicating that Nanobiotix is being referred to more favorably in the news media.

Company Overall Sentiment
Nurix Therapeutics Neutral
Nanobiotix Very Positive

Nurix Therapeutics presently has a consensus target price of $29.31, suggesting a potential upside of 161.49%. Nanobiotix has a consensus target price of $8.00, suggesting a potential upside of 52.09%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than Nanobiotix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.82
Nanobiotix
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Nurix Therapeutics beats Nanobiotix on 8 of the 14 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBTX vs. The Competition

MetricNanobiotixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$249.81M$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E RatioN/A4.4521.0120.09
Price / Sales6.33709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book-3.485.008.125.65
Net Income-$73.73M$30.99M$3.25B$257.91M
7 Day Performance-0.19%1.69%0.97%2.09%
1 Month Performance20.09%9.20%7.36%11.13%
1 Year Performance-5.23%-1.25%31.31%18.40%

Nanobiotix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBTX
Nanobiotix
2.6844 of 5 stars
$5.26
+0.8%
$8.00
+52.1%
-1.9%$249.81M$39.18M0.00100
NRIX
Nurix Therapeutics
2.4806 of 5 stars
$12.69
+2.0%
$29.38
+131.5%
-44.5%$970.15M$54.55M-4.86300Analyst Forecast
Analyst Revision
SANA
Sana Biotechnology
3.2939 of 5 stars
$4.22
+1.0%
$9.17
+117.2%
-30.3%$951.51MN/A-4.80380Positive News
Gap Up
LENZ
LENZ Therapeutics
1.3396 of 5 stars
$33.73
-2.8%
$46.60
+38.2%
+58.5%$949.37MN/A-19.06110
ZYME
Zymeworks
3.1341 of 5 stars
$13.35
+0.1%
$21.00
+57.3%
+43.1%$930.27M$93.38M-8.90460News Coverage
ORIC
Oric Pharmaceuticals
4.5055 of 5 stars
$10.85
-2.3%
$18.57
+71.2%
+9.0%$924.64MN/A-5.8080
NAGE
Niagen Bioscience
1.6525 of 5 stars
$11.26
-0.4%
$13.22
+17.4%
N/A$886.95M$99.60M66.24120
MENS
Jyong Biotech
N/A$11.61
+16.0%
N/AN/A$882.71MN/A0.0031Positive News
Gap Up
SION
Sionna Therapeutics
N/A$19.94
-2.4%
$38.50
+93.1%
N/A$879.75MN/A0.0035
REPL
Replimune Group
4.1427 of 5 stars
$11.28
+2.8%
$20.83
+84.7%
+17.6%$869.58MN/A-3.67210News Coverage
Analyst Forecast
Options Volume
High Trading Volume
GHRS
GH Research
2.0631 of 5 stars
$16.49
+3.9%
$32.00
+94.1%
+46.1%$857.94MN/A-20.8710Analyst Revision

Related Companies and Tools


This page (NASDAQ:NBTX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners